Vinge advises Cellink in conjunction with the acquisition of cytena
Vinge has advised Cellink AB (publ) in connection with the acquisition of all shares in cytena GmbH. cytena is a life science company which focuses on single cell technologies.
Vinge advises Surgical Science Sweden AB
Vinge advises Surgical Science Sweden AB in the acquisition of SenseGraphics and the related rights issue to finance it.
Vinge advises Smart Eye in a directed new share issue of MSEK 200
Vinge has advised Smart Eye AB (Nasdaq First North) on a directed new share issue that provides Smart Eye with approximately MSEK 200.
Vinge advises CELLINK in conjunction with the acquisition of Dispendix GmbH
Vinge has advised CELLINK AB, listed on First North Stockholm, in connection with the acquisition of all shares in Dispendix GmbH. Dispendix’s operations focus on bio dispensing technology and its patented technology emanates from a 10-year development within the German research institute Fraunhofer.
Vinge advised Adfenix AB in connection with capital procurement
Vinge has advised Adfenix AB in connection with Notion Capital’s and Industrifonden’s investment in the company.
Vinge advises Stirling Square Capital Partner
DOCU is a market leader in the Nordic region within the mediation of B2B chain-based information to the building industry as well as marketing information within the real estate and health care sectors.
Vinge advises on the acquisition of the advertising agency CP+B
Vinge has advised management in conjunction with the acquisition of the advertising agency CP+B.